The usefulness of preoperative 18FDG positron-emission tomography and computed tomography for predicting the malignant potential of gastrointestinal stromal tumors

Digestive Surgery

Volumn 31, Issue 2, 2014, Pages 79-86

  Tokumoto, Noriaki ^a   Tanabe, Kazuaki ^a   Misumi, Toshihiro ^a   Fujikuni, Nobuaki ^a   Suzuki, Takahisa ^b   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b CHUGOKU ELECTRIC POWER CO INC   (Japan)

Author keywords

Fletcher's risk categories; Gastrointestinal stromal tumor; Maximum standardized uptake value; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; CELL TRANSFORMATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMAN; MALE; MIDDLE AGED; MITOSIS INDEX; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROCEDURES; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84899601901     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000357149     Document Type: Article

References (18)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580. (Pubitemid 28067289)
2. Kitamura Y, Hirota S, Nishida T: Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. Ann Chir Gynaecol 1998; 87:282-286.
3. Miettinen M, Lasota J: Gastrointestinal stro-mal tumors-definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12. (Pubitemid 32128184)
4. Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, Otani Y, Shimada Y, Takahashi F, Kubota T: Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol 2008; 13:416-430.
5. Fletcher CD: Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol 2002; 33:455. (Pubitemid 34747862)
6. Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H: Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007; 42:633-641. (Pubitemid 46633822)
7. Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, Nishitani H: Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest 2010; 57:270-274.
8. Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, Morimoto S, Miyatani T, Kashihara H, Takasu C, Matsumoto N: The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. Surg Today 2013; 43:1162-1167.
9. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465. (Pubitemid 34747864)
10. Park JW, Cho CH, Jeong DS, Chae HD: Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric gist: predicting malignant potential pre-operatively. J Gastric Cancer 2011; 11:173-179.
11. Kamiyama Y, Aihara R, Nakabayashi T, Mo-chiki E, Asao T, Kuwano H, Oriuchi N, Endo K: 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stro-mal tumors. World J Surg 2005; 29:1429-1435. (Pubitemid 41712677)
12. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, Mc-Clure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glab beke M, van Oosterom A, Demetri GD: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16:566-578. (Pubitemid 40613322)
13. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR: Results of tyro-sine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245:347-352. (Pubitemid 46673128)
14. Wong NA, Young R, Malcomson RD, Nayar AG, Jamieson LA, Save VE, Carey FA, Brew-ster DH, Han C, Al-Nafussi A: Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohisto-chemical study of 108 resected cases of the stomach. Histopathology 2003; 43:118-126. (Pubitemid 36963155)
15. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor ty-rosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. (Pubitemid 351264358)
16. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M: Phase II trial of neoadjuvant/adjuvant imatinib mesyl-ate (IM) for advanced primary and metastat-ic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99:42-47.
17. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Cor-less CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesyl-ate for patients with unresectable or metastat-ic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625. (Pubitemid 351264357)
18. Fujimoto Y, Nakanishi Y, Yoshimura K, Shi-moda T: Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6: 39-48. (Pubitemid 36460555)